loader2
Partner With Us NRI

Thyrocare Technologies Ltd share Price Today

Company details

648.95
657.45
474.10
722.65
6M Return 5.33%
1Y Return 40.12%
Mkt Cap.(Cr) 3,458.63
Volume 42,676
Div Yield 2.76%
OI
-
OI Chg %
-
Volume 42,676

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Healthcare Services firm Thyrocare Technologies declares Q4FY22 result:

  • Revenue from operations of Rs. 562 Crore, grown by 18% YoY. Revenue for the final quarter of the year of Rs. 123 Crore, grown by 12% in sequential quarters mainly with revival of the base non covid business. Revenue from COVID business was flat in sequential quarters despite of 3rd wave in January. Non Covid business however revived significantly and surpassed the pre-COVID business. Continued focus on B2B business enabled us to garner lost volumes. Revenue and volumes for the month of March were all time high
  • Gross margin for the year improved mainly on account of reduction in the covid reagent/ consumables, however to enable growth aggressive prices are offered in the last quarter on routine non aarogyam tests and certain aarogyam profiles that has lead to impact on Q4 gross margins which shall settle down in the coming period.
  • Absolute EBITDA of Rs. 231 crore, grown by 35% YoY, mainly on account of better EBITDA margins on account of lower reagent/ consumable and operations cost in Government COVID business. The EBITDA margin at 41% for the year were tampered down in the last two quarters mainly on account of impact on the topline due to erosion of high margin government contract business, aggressive discounts to the network on some routine tests/ profiles to revive the business, spendings on manpower in particular growth teams to sustain growth and infrastructure to improve turnaround time to the patients.
  • 4.40 million COVID RTPCR tests were performed in the year, though despite 3 rd wave in January only 0.41 million were performed in the last quarter, thereby the focus is now shifted to non COVID segment.
  • Total 21.07 million samples (including COVID) sourced from 16.32 million patients (including COVID) were processed during current year.
  • 110.30 million tests were processed in the current year that includes standalone tests, COVID tests and tests included in the preventive care Aarogyam profiles.
  • Pathology business grew by 12% in sequential quarter and yearly by 18%. Growth in the current quarter was mainly on account of revival of B2B non COVID business
  • Radiology business accounted for about 5% of reported consolidated revenue of Thyrocare Group revived significantly after complete shut down for couple of months in covid and thereafter out of the impact of lockdowns, posting 34% YOY growth in the current year
  • Consolidated annual revenue of the group grew by 19% YOY, with positive signs of revival in non covid business. COVID business significantly eroded in last two quarters and radiology business growing at pre COVID level.

 

 

 

Result PDF

View Other Company Results

Thyrocare Technologies Ltd shares SWOT Analysis

Strengths (6)

  • Strong Momentum: Price above short, medium and long term moving averages
  • Growth in Net Profit with increasing Profit Margin (QoQ)
  • Growth in Quarterly Net Profit with increasing Profit Margin (YoY)

Weakness (2)

  • Declining Net Cash Flow : Companies not able to generate net cash
  • Companies with High Promoter Pledge

Opportunity (2)

  • Negative to Positive growth in Sales and Profit with Strong Price momentum
  • RSI indicating price strength

Threats (2)

  • High PE (PE > 40)
  • Increasing Trend in Non-Core Income

Resistance and support

R1 657.4
R2 661.7
R3 665.9
Pivot

653.18

S1 648.9
S2 644.7
S3 640.4
EMA SMA
630.7
629.0
623.9
609.6
625.4
630.5
627.3
605.0
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
SOCIETE GENERALE Bulk Purchase 2023-06-21 527.93 296123 NSE
ICICI PRUDENTIAL MUTUAL FUND Bulk Purchase 2023-06-20 488 1184131 BSE
ICICI PRUDENTIAL MUTUAL FUND Bulk Purchase 2023-06-20 488 764947 BSE
Name Category Shares
Docon Technologies Private Limited PROMOTER 71.11%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Thyrocare Technologies Ltd Stocks COMPARISON

Financials( in Cr) Thyrocare Technologies Ltd Max Healthcare Institute Ltd Apollo Hospitals Enterprise Ltd Fortis Healthcare Ltd Global Health Ltd
Price 653.15 927.90 6,207.60 502.25 1,356.20
% Change -0.29 4.25 0.02 3.99 6.17
Mcap Cr 3,458.63 90,183.71 89,255.98 37,917.77 36,414.92
Revenue TTM Cr 526.67 4,831.37 16,612.50 6,537.06 2,694.25
Net Profit TTM Cr 64.36 1,103.51 887.50 632.98 326.08
PE TTM 48.87 85.36 99.43 64.55 76.14
1 Year Return 40.12 60.94 25.38 74.57 116.27
ROCE 16.86 13.85 14.16 7.51 16.49
ROE 12.13 16.12 15.04 6.79 16.13
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 515.38 Cr FV: 10.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 32,317.57 -2,589.17
LAST 3M 111,725.82 -36,230.77
LAST 6M 182,653.52 -16,910.03
LAST 12M 290,144.87 98,834.05
Thyrocare Technologies Limited - Updates

Jun 11, 2024 l NSE Announcement

Thyrocare Technologies Limited - Copy of Newspaper Publication

Jun 10, 2024 l NSE Announcement

Date Action Type Ratio
Apr 20, 2023 Dividend 180
May 11, 2022 Dividend 150

Thyrocare Technologies Ltd Information

Stock PE (TTM)
48.87
Promoter Holding
71.11%
Book Value
99.4799
ROCE
16.86%
ROE
12.13%
Registered Address

D-37/1 TTC Industrial Area, MIDC Turbhe, Navi Mumbai, Maharashtra, 400703

Tel : 91-22-27622762
Email : ramjee.d:thyrocare.com; enquiry:thyrocare.com
Website : http://www.thyrocare.com
Registrar

Link Intime India Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 539871
NSE Code : THYROCARE
Book Closure Date (Month) :
BSE Group : B
ISIN : INE594H01019

FAQ’s on Thyrocare Technologies Ltd Shares

You can buy Thyrocare Technologies Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Thyrocare Technologies Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jun 14, 2024 03:45 PM the closing price of Thyrocare Technologies Ltd was Rs.653.15.

The latest PE ratio of Thyrocare Technologies Ltd as of Jun 14, 2024 03:45 PM is 48.87

The latest PB ratio of Thyrocare Technologies Ltd as of Jun 14, 2024 03:45 PM is 0.15

The 52-week high of Thyrocare Technologies Ltd share price is Rs. 722.65 while the 52-week low is Rs. 474.10

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jun 14, 2024 03:45 PM, the market cap of Thyrocare Technologies Ltd stood at Rs. 3,458.63.

Download App

Download Our App

Play Store App Store
market app